Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma

Asthma Clinical Trial

— DIVE  

Official title:

Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma (DIVE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05992519
• Other study ID #: 2023-4791
• Status: Recruiting
• Start date: November 7, 2022
• Est. completion date: November 1, 2026

Study information

• Verified date: February 2024
• Source: Université de Sherbrooke
• Contact: Simon Couillard, MD MSc
• Phone: +1-819-346-1110
• Email: s.couillard[@]usherbrooke.ca
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Asthma is characterised by episodic symptoms (attacks) caused by airway inflammation and decreased airflow to the lungs. It affects 10% of the Canadian population and is the most common chronic disease in childhood. Despite its burden and its potential to be life-threatening, establishing the diagnosis takes time due to difficulty in accessing specialised breathing tests. Indeed, the current diagnostic strategy relies on a breathing test (spirometry) and, if non-diagnostic, a subsequent more complicated breathing test conducted in hospitals (a bronchial provocation test). Our dependence on the latter test must be confronted to the bottleneck created by our reliance on it and the difficulty to do these tests in children. Furthermore, within the current framework, people receiving a diagnosis do not know if they have active airway inflammation - a key feature with predicts increased susceptibility to asthma attacks and treatment responsiveness. Our study's goal is to validate clinically accessible and useful diagnostic tests for peoplesuspected to have asthma. Specifically, we are interested in alternative tests that are a) achievable outside the hospital; b) useful markers of airway inflammation/risk c) can identify people at with a higher likelihood of responding to anti-inflammatory therapy. The two tests we are mainly interested in are: - Exhaled nitric oxide (measured with a portable handheld machine) - The blood eosinophil count (obtained on a general blood test) +/- Other tests which we might be able to develop within this cohort (e.g. urine tests)

Description:

BACKGROUND Asthma affects 10% of the general population but remains a diagnostic challenge. Considering the difficult access, weak specificity, and low clinical utility of bronchial provocation tests, more effective diagnostic methods are needed. Blood eosinophils and exhaled nitric oxide (FeNO) are biomarkers of type-2 inflammation that have established mechanistic, prognostic and theragnostic values in chronic asthma. Specifically, these biomarkers identify attack-prone patients with ongoing alarmin, type-2 cytokine, and chemokine signalling at the epithelial level driving airway hyperresponsiveness and accelerated lung function decline. Most importantly, these biomarkers also identify those who benefit the most from anti-inflammatory therapy. Considering the above clinical utilities, using biomarkers in primary care to diagnose airways disease in people with suspected asthma would represent a very effective diagnostic strategy. HYPOTHESIS: In people with non-diagnostic spirometry and asthma suspected by primary care, measuring blood eosinophils and FeNO is a feasible diagnostic strategy with good accuracy and the added value of early mechanistic insight in epithelial signalling pathways. OBJECTIVE: To estimate the diagnostic performance parameters of type-2 biomarkers in people with suspected asthma and a non-diagnostic spirometry. An exploratory analysis of inflammatory proteins (alarmin, type-2 cytokines, chemokines) in the nasal epithelial lining fluid (NELF) and serum according to biomarkers will be conducted. This and other secondary exploratory objectives will lead to better mechanistic and operational insight on the value of type-2 biomarkers in early disease. METHODS: The investigators propose a prospective observational study on the logistical feasibility, receiver operating characteristics (ROC), and mechanistic value of point-of-care type-2 inflammatory biomarkers to diagnose asthma (Figure). The study will include 123 people ≥12 years old with non-diagnostic pre-postbronchodilator spirometry referred by primary care for a methacholine challenge via the Suspected Asthma pathway of the Centre Hospitalier Universitaire de Sherbrooke. After the methacholine challenge, patients will complete questionnaires, have blood eosinophils measured (by venous blood sample and point-of-care (POC) capillary blood), FeNO measured (by electroluminescence and POC strip-tests), nasosorption performed, and serum harvested for allergy testing and inflammatory protein measurement. OUTCOMES: The main analysis will be ROC plots of (1) FeNO alone; (2) blood eosinophils alone; and (3) the combination of blood eosinophils and FeNO;. The ROC plot will be based on a methacholine provocative dose ≤200 mcg (~ provocative concentration ≤8 mg/mL). The target sample size of 123 will have 90% power to compute 3 ROC curves' area under the curve (AUC) ≥ 0.7 significantly different from the null hypothesis (AUC=0.5) with a conservatively corrected two-sided α error < 0.016, assuming a positive/negative case ratio of 2. Secondary outcomes are the diagnostic and cost-effectiveness of blood eosinophil and FeNO measurement compared to methacholine challenges; and univariate plus multivariate modelling between blood eosinophils, FeNO, and inflammatory proteins (alarmins TSLP and IL-33; type-2 cytokines IL-4, -5, -13; chemokines eotaxin-3 and TARC) measured in the NELF and serum, or metabolites measured in the urine. EXPECTED RESULTS: It is expected that type-2 inflammometry to be a useful alternative diagnostic pathway with benefits extending beyond diagnostic accuracy thanks to early insight into the inflammatory phenotype. IMPACT: This observational study will support further validation studies and/or trials assessing POC biomarker-assisted diagnosis and management of asthma in the community setting. Measuring biomarkers at the time of diagnosis could facilitate a 'predict and prevent' approach to diagnostic algorithms in airway disease

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 123
• Est. completion date: November 1, 2026
• Est. primary completion date: November 1, 2025
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• aged = 12 years who have symptoms suggestive of asthma,
• referred by their primary care provider (defined as a non-respirologist, non-allergist, non-otolaryngologist) using the CHUS suspected asthma decision-making algorithm. Under that algorithm, patients have non-diagnostic pre- and post-bronchodilator spirometry and no contraindications to a methacholine challenge.
• Free and informed consent must be given by the patient (and their legal guardian, if applicable).

Exclusion Criteria:

• Use of an inhaled or systemic corticosteroid in the previous 48 hours;
• Smoking in the previous 6 hours; history of viral and/or bacterial respiratory infection in the past 4 weeks;
• major cardiopulmonary disease, including: a) chronic obstructive pulmonary disease (COPD), defined by all of the following: i) aged = 40 years , ii) permanent obstruction on spirometry (FEV1/FVC <0.7) and iii) a smoking history of >10 pack-years or known alpha-1-antitrypsin deficiency, b) lung conditions deemed significant by the investigator, including cystic fibrosis and bronchiectasis, and c) unstable heart disease.

Related Conditions & MeSH terms

• Asthma
• Asthma in Children
• Diagnosis
• Inflammation

Intervention

Diagnostic Test:
• ¸FeNO
FeNO measured with a NIOX VERO device after the methacholine challenge

Locations

Country	Name	City	State
Canada	Centre de Recherche du CHUS	Sherbrooke	Quebec

Sponsors (6)

Lead Sponsor	Collaborator
Université de Sherbrooke	Association pulmonaire du Québec, AstraZeneca, Fondation JA DeSève, Fonds de la Recherche en Santé du Québec, Réseau de Recherche en Santé Respiratoire du Québec

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC of the ROC analysis to diagnose asthma	Diagnosis of asthma defined as a methacholine PD20 < 200 mcg	FeNO measured on the day of the methacholine challenge (i.e. Baseline visit)
Primary	Blood eosinophil count: ROC analysis AUC to diagnose asthma	Diagnosis of asthma defined as a methacholine PD20 < 200 mcg	Blood eosinophils measured on the day of the methacholine challenge (i.e. Baseline visit)
Primary	Combination of FeNO + Blood eosinophil count: ROC analysis AUC to diagnose asthma	Diagnosis of asthma defined as a methacholine PD20 < 200 mcg	FeNO and blood eosinophils measured on the day of the methacholine challenge (i.e. Baseline visit)
Secondary	Univariate association between biomarkers (blood eosinophils and FeNO) and inflammatory proteins/metabolites	Inflammatory proteins/metabolites measured in the NELF, serum, and urine. Further exploratory multivariate modelling adjusting for atopy (defined as a history of eczema, rhinoconjunctivitis, or food allergy and/or at least one sensitisation to an airbourne sensitiser) and biological sex.	Baseline
Secondary	Operational efficacy of the use of biomarkers as a diagnostic tool:	Potential reduction in diagnostic delay in asthma patients: the difference (in days) between the date of the challenge test and the date of the request; Time difference (in minutes/days) for diagnosing asthma using biomarkers (FeNO + eosinophilia) versus a methacholine challenge.; Cost difference between the use of biomarkers (traditional or point-of-care analysed separately) as 2nd diagnosis step versus a standard methacholine challenge test.	Baseline
Secondary	Concordance between traditional biomarker measurements (FeNO using Niox Vero and eosinophils in venous blood) and the new POC method (capillary eosinophils using Sight OLO).	Intraclass correlation coefficient (both sides, mixed model for absolute concordance, single measurements); Estimated fixed Bland-Altman bias for the gold standard versus point-of-care	Baseline
Secondary	Biomarker level in asthmatic patients at time of diagnosis	Expressed as n (%) of diagnosed patients per square in a 3×3 grid stratified by combination of biomarkers (eosinophils <0.15, 0.015-<0.30, =0.30×109/L; FeNO <25, 25-<50, =50 ppb)	Baseline